Report cover image

Artificial Intelligence in Drug Discovery Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Nov 01, 2024
Length 150 Pages
SKU # FOB19302793

Description

Artificial Intelligence in Drug Discovery Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Artificial Intelligence in Drug Discovery Market

The global artificial intelligence in drug discovery market size was valued at USD 3.00 billion in 2022 and is projected to grow from USD 3.54 billion in 2023 to USD 7.94 billion by 2030, exhibiting a CAGR of 12.2% during the forecast period of 2023-2030.

COVID-19 has triggered the use of Artificial Intelligence in drug discovery, as the scientific world scrambles for vaccines and treatments for the virus. This urgency has led to increase in cooperation between tech companies and prescribed drugs, thus enhanced the AI algorithms for green drug discovery, which has in one way hindered the artificial intelligence in drug discovery market growth.

Artificial Intelligence in the Drug Discovery Market is driven by the aid of way of the want for quicker drug development, improvements in machines getting to, and the prices of traditional techniques. Increased biomedical facts and a name for personalized treatment further promote AI adoption.

Generative AI and gadget learning are revolutionizing the drug discovery procedure by permitting the layout of new drug molecules with preferred houses. AI algorithms can analyze sizable quantities of information to perceive patterns and trends, accelerating the identity of capacity drug candidates and expanding the artificial intelligence in drug discovery market share globally. Additionally, AI can, as should be expected, use protein systems that are critical for information on how tablets engage with their goals. This aggregate of AI and gadgets getting to know technology is appreciably rushing the drug discovery method and improving the probability of growing powerful new treatments.

Comprehensive Analysis of Artificial Intelligence in Drug Discovery Market

Artificial Intelligence in the Drug Discovery Market has been categorized by drug type into small molecules and massive molecules and imparted into software programs and services with the aid of technology into system learning, herbal language processing, and so on. with the assistance of utility into oncology, neurology, cardiology, and so on.; and with the help of quit- consumer into pharmaceutical and biotechnological groups, instructional and studies institutes, and others. Small molecules dominate the marketplace due to cost-effectiveness and abundant medical information, while the software phase leads to innovation. Machine learning is the crucial era riding efficiency, particularly in oncology, which is a blessing from elevated medical trials and investment. Pharmaceutical businesses lead the quit-user phase through strategic collaborations to integrate AI in drug discovery.

The North America region led the artificial intelligence in drug discovery market by benefitting a size of USD 2.08 billion in 2022 due to the robust presence of pharmaceutical groups and their strategic partnerships with firms imparting synthetic intelligence answers.

The leading players in Artificial Intelligence in the Drug Discovery market play a crucial role in shaping its growth trajectory and establishing industry standards. Key players such as Microsoft (U.S.), Schrödinger, Inc. (U.S.), Cresset (U.K.), IBM (U.S.), Atomwise Inc. (U.S.), Insilico Medicine (U.S.), Exscientia (U.K.), BenevolentAI (U.K.), Aria Pharmaceuticals, Inc. (U.S.), Integral BioSciences (U.S.), and Alphabet Inc. (U.S.) contribute to a competitive landscape that drives innovation and advancements in the market.

In November 2022, Cyclica presented a provide of USD 1.8 million from the Bill & Melinda Gates Foundation to utilize its artificial intelligence-pushed drug discovery platform for figuring out new non-hormonal contraceptives by harnessing various low-data biological objectives.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2017-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2017-2021

Growth Rate CAGR of 12.2% from 2023 to 2030

Unit Value (USD Billion)

Segmentation By Drug Type, Offering, Technology, Application, End-user, and Region

By Drug Type

Small Molecule

Large Molecule

By Offering

Software

Services

By Technology

Machine Learning

Natural Language Processing

Others

By Application

Endocrinology

Cardiology

Oncology

Neurology

Others

By End-user

Pharmaceutical & Biotechnological Companies

Academic & Research Institutes

Others

By Region

North America (By Drug Type, Offering, Technology, Application, End-user, and Country)

U.S.

Canada

Europe (By Drug Type, Offering, Technology, Application, End-user, and Country/Sub-Region)

U.K.

Germany

France

Italy

Spain

Scandinavia

Rest of Europe

Asia Pacific (By Drug Type, Offering, Technology, Application, End-user, and Country/Sub-Region)

Japan

China

India

Australia

Southeast Asia

Rest of Asia Pacific

Latin America (By Drug Type, Offering, Technology, Application, End-user, and Country/Sub-Region)

Brazil

Mexico

Rest of Latin America

Middle East & Africa (By Drug Type, Offering, Technology, Application, End-user, and Country/Sub-Region)

GCC

South Africa

Rest of the Middle East & Africa


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

150 Pages
1. Introduction
1.1. Market Scope
1.2. Market Segmentation
1.3. Market Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2022
4.2. Key Industry Developments - Mergers, Acquisitions & Partnerships, By Key Players
4.3. Applications of Artificial Intelligence/Machine Learning in Drug Discovery
4.4. Overview of Techniques and Technologies Used in Drug Discovery
4.5. Impact of COVID-19 on the Market
5. Global Artificial Intelligence in Drug Discovery Market Analysis, Insights and Forecast, 2017-2030
5.1. Market Analysis, Insights and Forecast – By Drug Type
5.1.1. Small Molecule
5.1.2. Large Molecule
5.2. Market Analysis, Insights and Forecast – By Offerings
5.2.1. Software
5.2.2. Services
5.3. Market Analysis, Insights and Forecast – By Technology
5.3.1. Machine Learning
5.3.2. Natural Language Processing
5.3.3. Others
5.4. Market Analysis, Insights and Forecast – By Application
5.4.1. Endocrinology
5.4.2. Cardiology
5.4.3. Oncology
5.4.4. Neurology
5.4.5. Others
5.5. Market Analysis, Insights and Forecast – By End-User
5.5.1. Pharmaceutical & Biotechnological Companies
5.5.2. Academic & Research Institutes
5.5.3. Others
5.6. Market Analysis, Insights and Forecast – By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia Pacific
5.6.4. Latin America
5.6.5. Middle East & Africa
6. North America Artificial Intelligence in Drug Discovery Market Analysis, Insights and Forecast, 2017-2030
6.1. Market Analysis, Insights and Forecast – By Drug Type
6.1.1. Small Molecule
6.1.2. Large Molecule
6.2. Market Analysis, Insights and Forecast – By Offerings
6.2.1. Software
6.2.2. Services
6.3. Market Analysis, Insights and Forecast – By Technology
6.3.1. Machine Learning
6.3.2. Natural Language Processing
6.3.3. Others
6.4. Market Analysis, Insights and Forecast – By Application
6.4.1. Endocrinology
6.4.2. Cardiology
6.4.3. Oncology
6.4.4. Neurology
6.4.5. Others
6.5. Market Analysis, Insights and Forecast – By End-User
6.5.1. Pharmaceutical & Biotechnological Companies
6.5.2. Academic & Research Institutes
6.5.3. Others
6.6. Market Analysis, Insights and Forecast – By Country
6.6.1. U.S.
6.6.2. Canada
7. Europe Artificial Intelligence in Drug Discovery Market Analysis, Insights and Forecast, 2017-2030
7.1. Market Analysis, Insights and Forecast – By Drug Type
7.1.1. Small Molecule
7.1.2. Large Molecule
7.2. Market Analysis, Insights and Forecast – By Offerings
7.2.1. Software
7.2.2. Services
7.3. Market Analysis, Insights and Forecast – By Technology
7.3.1. Machine Learning
7.3.2. Natural Language Processing
7.3.3. Others
7.4. Market Analysis, Insights and Forecast – By Application
7.4.1. Endocrinology
7.4.2. Cardiology
7.4.3. Oncology
7.4.4. Neurology
7.4.5. Others
7.5. Market Analysis, Insights and Forecast – By End-User
7.5.1. Pharmaceutical & Biotechnological Companies
7.5.2. Academic & Research Institutes
7.5.3. Others
7.6. Market Analysis, Insights and Forecast – By Country/Sub-region
7.6.1. U.K.
7.6.2. Germany
7.6.3. France
7.6.4. Italy
7.6.5. Spain
7.6.6. Scandinavia
7.6.7. Rest of Europe
8. Asia Pacific Artificial Intelligence in Drug Discovery Market Analysis, Insights and Forecast, 2017-2030
8.1. Market Analysis, Insights and Forecast – By Drug Type
8.1.1. Small Molecule
8.1.2. Large Molecule
8.2. Market Analysis, Insights and Forecast – By Offerings
8.2.1. Software
8.2.2. Services
8.3. Market Analysis, Insights and Forecast – By Technology
8.3.1. Machine Learning
8.3.2. Natural Language Processing
8.3.3. Others
8.4. Market Analysis, Insights and Forecast – By Application
8.4.1. Endocrinology
8.4.2. Cardiology
8.4.3. Oncology
8.4.4. Neurology
8.4.5. Others
8.5. Market Analysis, Insights and Forecast – By End-User
8.5.1. Pharmaceutical & Biotechnological Companies
8.5.2. Academic & Research Institutes
8.5.3. Others
8.6. Market Analysis, Insights and Forecast – By Country/Sub-region
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Australia
8.6.5. Southeast Asia
8.6.6. Rest of Asia Pacific
9. Latin America Artificial Intelligence in Drug Discovery Market Analysis, Insights and Forecast, 2017-2030
9.1. Market Analysis, Insights and Forecast – By Drug Type
9.1.1. Small Molecule
9.1.2. Large Molecule
9.2. Market Analysis, Insights and Forecast – By Offerings
9.2.1. Software
9.2.2. Services
9.3. Market Analysis, Insights and Forecast – By Technology
9.3.1. Machine Learning
9.3.2. Natural Language Processing
9.3.3. Others
9.4. Market Analysis, Insights and Forecast – By Application
9.4.1. Endocrinology
9.4.2. Cardiology
9.4.3. Oncology
9.4.4. Neurology
9.4.5. Others
9.5. Market Analysis, Insights and Forecast – By End-User
9.5.1. Pharmaceutical & Biotechnological Companies
9.5.2. Academic & Research Institutes
9.5.3. Others
9.6. Market Analysis, Insights and Forecast – By Country/Sub-region
9.6.1. Brazil
9.6.2. Mexico
9.6.3. Rest of Latin America
10. Middle East & Africa Artificial Intelligence in Drug Discovery Market Analysis, Insights and Forecast, 2017-2030
10.1. Market Analysis, Insights and Forecast – By Drug Type
10.1.1. Small Molecule
10.1.2. Large Molecule
10.2. Market Analysis, Insights and Forecast – By Offerings
10.2.1. Software
10.2.2. Services
10.3. Market Analysis, Insights and Forecast – By Technology
10.3.1. Machine Learning
10.3.2. Natural Language Processing
10.3.3. Others
10.4. Market Analysis, Insights and Forecast – By Application
10.4.1. Endocrinology
10.4.2. Cardiology
10.4.3. Oncology
10.4.4. Neurology
10.4.5. Others
10.5. Market Analysis, Insights and Forecast – By End-User
10.5.1. Pharmaceutical & Biotechnological Companies
10.5.2. Academic & Research Institutes
10.5.3. Others
10.6. Market Analysis, Insights and Forecast – By Country/Sub-region
10.6.1. GCC
10.6.2. South Africa
10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Global Market Share Analysis (2022)
11.2. Company Profiles
11.2.1. Microsoft
11.2.1.1. Overview
11.2.1.2. Products
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Strategies
11.2.1.6. Financials (Based on Availability)
11.2.2. Schrödinger, Inc.
11.2.2.1. Overview
11.2.2.2. Products
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Strategies
11.2.2.6. Financials (Based on Availability)
11.2.3. Cresset
11.2.3.1. IBM
11.2.3.2. Overview
11.2.3.3. Products
11.2.3.4. SWOT Analysis
11.2.3.5. Recent Developments
11.2.3.6. Strategies
11.2.3.7. Financials (Based on Availability)
11.2.4. Atomwise Inc.
11.2.4.1. Overview
11.2.4.2. Products
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Strategies
11.2.4.6. Financials (Based on Availability)
11.2.5. Insilico Medicine
11.2.5.1. Overview
11.2.5.2. Products
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Strategies
11.2.5.6. Financials (Based on Availability)
11.2.6. Exscientia
11.2.6.1. Overview
11.2.6.2. Products
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Strategies
11.2.6.6. Financials (Based on Availability)
11.2.7. BenevolentAI
11.2.7.1. Overview
11.2.7.2. Products
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Strategies
11.2.7.6. Financials (Based on Availability)
11.2.8. Aria Pharmaceuticals, Inc.
11.2.8.1. Overview
11.2.8.2. Products
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Strategies
11.2.8.6. Financials (Based on Availability)
11.2.9. Integral BioSciences
11.2.9.1. Overview
11.2.9.2. Products
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Strategies
11.2.9.6. Financials (Based on Availability)
11.2.10. Alphabet Inc.
11.2.10.1. Overview
11.2.10.2. Products
11.2.10.3. SWOT Analysis
11.2.10.4. Recent Developments
11.2.10.5. Strategies
11.2.10.6. Financials (Based on Availability)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us